Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Código QR

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Michael B Horsley, Malik Y KahookRocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO, USAPurpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael B Horsley, Malik Y Kahook
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e7c879c638b04f038a3d0a356839b42a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
por: Schmier JK, et al.
Publicado: (2014)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
por: Takagi Y, et al.
Publicado: (2018)

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2010)

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
por: Anne J Lee, et al.
Publicado: (2010)

Quality of life of glaucoma patients under medical therapy with different prostaglandins
por: Paletta Guedes RA, et al.
Publicado: (2012)

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis
por: Oghenowede Eyawo, et al.
Publicado: (2009)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz K, et al.
Publicado: (2011)

Challenges in the clinical measurement of ocular surface disease in glaucoma patients
por: Pflugfelder SC, et al.
Publicado: (2011)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
por: Tamçelik N, et al.
Publicado: (2017)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer A, et al.
Publicado: (2011)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
por: Kenji Inoue, et al.
Publicado: (2011)

Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid
por: Lawrence Y Ho, et al.
Publicado: (2008)

A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma
por: Garcia-Fejioo J, et al.
Publicado: (2012)

Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
por: Cvenkel B, et al.
Publicado: (2015)

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
por: Fukuda M, et al.
Publicado: (2013)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa VP, et al.
Publicado: (2012)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

First-year treatment costs among new initiators of topical prostaglandin analogs
por: Jordana K Schmier, et al.
Publicado: (2009)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
por: Inoue K, et al.
Publicado: (2012)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate N, et al.
Publicado: (2020)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
por: Seibold LK, et al.
Publicado: (2014)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe NM
Publicado: (2014)

First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
por: Jordana K Schmier, et al.
Publicado: (2010)

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
por: Masahiko Ayaki, et al.
Publicado: (2010)

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo JS, et al.
Publicado: (2016)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl I, et al.
Publicado: (2013)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
por: Anna Galanopoulos, et al.
Publicado: (2008)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
por: Figueiredo BP, et al.
Publicado: (2013)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
por: Mylla Boso AL, et al.
Publicado: (2020)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Scott D Smid
Publicado: (2009)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue K, et al.
Publicado: (2012)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients
por: Adam M Moss, et al.
Publicado: (2010)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009)

Ocular surface disease in posttrabeculectomy/mitomycin C patients
por: Lam J, et al.
Publicado: (2015)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella F, et al.
Publicado: (2012)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Emilio Rintaro Suzuki Jr, et al.
Publicado: (2010)

Patient satisfaction with glaucoma therapy: reality or myth?
por: Lemij HG, et al.
Publicado: (2015)